Components of the blood that cannot be assigned to one of the other above-mentioned groups of medicines.
| Name | Marketing Authorisation Holder | License Number | License Date | Further Information |
|---|---|---|---|---|
FEIBA 500 E. |
Takeda GmbH |
PEI.H.12158.01.1 | 20.03.2023 | |
FEIBA 500 E. konzentriert |
Takeda GmbH |
PEI.H.12158.04.1 | 20.01.2024 | |
FEIBA 1000 E. |
Takeda GmbH |
PEI.H.12158.02.1 | 20.03.2023 | |
FEIBA 1000 E. konzentriert |
Takeda GmbH |
PEI.H.12158.05.1 | 20.01.2024 | |
FEIBA 2500 E. |
Takeda GmbH |
PEI.H.12158.03.1 | 20.03.2023 | |
FEIBA 2500 E. konzentriert |
Takeda GmbH |
PEI.H.12158.06.1 | 20.01.2024 | |
|
Normosang |
Recordati Rare Diseases |
PEI.H.03381.01.1 | 15.10.2006 | |
|
Ondexxya |
Astrazeneca AB |
EU/1/18/1345 | 26.04.2019 | |
Prolastin |
Grifols Deutschland GmbH |
12944.01.00 | 14.12.1988 | |
Prolastin 4000 mg |
Grifols Deutschland GmbH |
12944.02.00 | 04.10.2023 | |
Prolastin 5000 mg |
Grifols Deutschland GmbH |
12944.03.00 | 04.10.2023 | |
|
Respreeza |
CSL Behring GmbH |
EU/1/15/1006 | 20.08.2015 |
The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.
The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.
As of: PEI announcement No. 520 in BAnz AT 22.08.2024 B6.
Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.
If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.
Updated: 22.08.2024
